Fingerprint
Dive into the research topics of 'Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
Shaji K. Kumar, Norbert Grzasko, Sosana Delimpasi, Wieslaw W. Jedrzejczak, Sebastian Grosicki, Marie Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A. Dimopoulos
Research output: Contribution to journal › Article › peer-review
10
Scopus
citations